Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid‐directed monoclonal antibody
نویسندگان
چکیده
FIONA HE, KEVIN HA, ZUZAN CAYCI, MARIA EVASOVICH SWENSON, M. LUIZA CARAMORI, KHALID AMIN, MICHAEL A. LINDEN, AND CELALETTIN USTUN* Division of Hematology-Oncology and Transplantation, Department of Medicine; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota; epartment of Radiology, University of Minnesota, Minneapolis, Minnesota; Department of Surgical Oncology, Minneapolis, Minnesota; Division of Diabetes, Endocrinology and Metabolism,Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
منابع مشابه
2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis †
Amyloid light chain (AL) amyloidosis is characterized by misfolded light chain (LC) (amyloid) deposition in various peripheral organs, leading to progressive dysfunction and death. There are no regulatory agency-approved treatments for AL amyloidosis, and none of the available standard of care approaches directly targets the LC protein that constitutes the amyloid. NEOD001, currently in late-st...
متن کاملThermal Stability Threshold for Amyloid Formation in Light Chain Amyloidosis
Light chain (AL) amyloidosis is a devastating disease characterized by amyloid deposits formed by immunoglobulin light chains. Current available treatments involve conventional chemotherapy and autologous stem cell transplant. We have recently concluded a phase III trial comparing these two treatments. AL amyloidosis patients who achieve hematological complete response (CR) do not necessarily a...
متن کاملDaratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.
The majority of patients with immunoglobulin light chain amyloidosis (AL) fail to achieve a complete response (CR) to standard light chain suppressive chemotherapy, and almost all patients eventually experience hematologic relapse and progression of organ involvement. Additional well-tolerated treatment options are needed. We present our retrospective experience of 25 consecutive previously tre...
متن کاملNew therapeutic perspectives – amyloid removal
Background In systemic amyloidosis, disease is caused by extracellular accumulation of amyloid fibrils which, unlike other interstitial debris, are not cleared and which disrupt tissue structure and function. Direct removal of amyloid deposits is required to preserve and possibly restore tissue and organ function. We are targeting serum amyloid P component (SAP) for this purpose. SAP normal pla...
متن کاملLight-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response
Amyloid light chain (AL) amyloidosis is a systemic disease characterised by the aggregation of misfolded immunoglobulin light chain (LC), predominantly in the heart and kidneys, causing organ failure. If untreated, the median survival of patients with cardiac AL amyloidosis is 6 months from the onset of heart failure. Protracted time to establish a diagnosis, often lasting >1 year, is a frequen...
متن کامل